~~<i id='10011151F5'><strike id='10011151F5'><tt id='10011151F5'><pre id='10011151F5'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：comprehensive 2025-08-15 07:39:29 Page View：33

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Telehealth options flood the market as retailers push virtual care
Next article： Novavax promises a turnaround & Lilly roils the obesity market

explore

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

Novavax promises a turnaround & Lilly roils the obesity market

SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

First Opinion Podcast: How to protect health care in times of war

Injusttwoweeks,thebrutalityoftheIsrael-Hamasconflicthasshockedtheworld.Butoneofitsmostheartbreakinga